MHRA Drug Safety Update: Valproate in Pregnancy
Covers new important information and strengthened warnings about the epileptic drug Valproate.
- children exposed in utero to valproate are at a high risk of serious developmental disorders and/or congenital malformations
- valproate should not be prescribed to women who are pregnant or of childbearing potential unless other treatments are ineffective or not tolerated
- valproate treatment must be started and supervised by a doctor experienced in managing epilepsy or bipolar disorder
- the benefits of treatment should be carefully balanced against the risks when prescribing valproate for the first time. Female patients must be made aware of the risks.
By en:User:Sponge [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons